Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor - SGLT2-inhibitor).

Subjects

Subjects :

Humans
Male
Middle Aged
Administration, Oral
Angioedema chemically induced
Angioedema diagnosis
Antibodies, Monoclonal, Humanized adverse effects
Antibodies, Monoclonal, Humanized therapeutic use
Antifungal Agents administration & dosage
Antifungal Agents therapeutic use
Benzhydryl Compounds adverse effects
Benzhydryl Compounds therapeutic use
Candida albicans isolation & purification
Fluconazole administration & dosage
Fluconazole therapeutic use
Foreskin pathology
Glucosides adverse effects
Glucosides therapeutic use
Missed Diagnosis
Penis pathology
Sodium-Glucose Transporter 2 Inhibitors administration & dosage
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Treatment Outcome
Candidiasis, Oral drug therapy
Candidiasis, Oral microbiology
Candidiasis, Oral pathology

Details

Language :

English

ISSN :

1610-0387

Volume :

17

Issue :

4

Database :

MEDLINE

Journal :

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Publication Type :

Report

Accession number :

30873750

Full Text :

https://doi.org/10.1111/ddg.13807